Hi guys, Welcome to the Advanced Video Search Engine, and you are watching DESTINY-Gastric03: trastuzumab deruxtecan in HER2-overexpressing gastric cancer. That video is uploaded by VJOncology at 2021-01-15T06:28:48-08:00. We are promoting this video only for entertainment and educational purpose only. So, I hope you like & enjoy it. [sICSJUcDPZI]
| Name | DESTINY-Gastric03: trastuzumab deruxtecan in HER2-overexpressing gastric cancer |
| Video Uploader | Video From VJOncology |
| Upload Date | This Video Uploaded At 15-01-2021 14:28:48 |
| Video Discription | Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the ongoing DESTINY-Gastric03 study (NCT04379596), a Phase Ib/II, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer. T-DXd is an antibody-drug conjugate containing an anti-HER2 antibody, which in Phase I studies, has shown promising antitumor activity. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology). sICSJUcDPZI |
| Category | Education |
| Tags | Speaker: Yelena Y. Janjigian | Institution: Memorial Sloan Kettering Cancer Center | Event: VJVirtual | Event: ASCO GI 2021 | Format: Interview | Subject: Gastrointestinal Cancer | Subject: Gastric Cancer | Field: Treatment | Field: Trial Updates | Field: Immuno-Oncology | Medicines: Trastuzumab Deruxtecan | Medicines: Antibodies | NCT04379596 | Trial: DESTINY-Gastric03 | Trial: DESTINY-Gastric01 | Medicines: Durvalumab | Medicines: Pembrolizumab |
